1.350USD+19.47%Mkt Cap: —P/E: —Today
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational prod…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value-784.97K $
Revenue (TTM)100.00K $
Gross Profit100.00K $
Net Income (TTM)-14.62M $
Revenue/Share0.0110 USD
Last Price1.350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.05
EV/Revenue-7.85
P/S—
P/B1.22
EPS (TTM)-0.39
EPS (Forward)—
52W Range
1.07056% of range1.570
52W High1.570 USD
52W Low1.070 USD
Profitability
Gross Margin100.00%
Oper. Margin-16426.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-101.66%
ROA-56.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.32M $
CapEx (TTM)—
FCF Margin-8100.25%
FCF Yield—
Net Debt-10.44M $
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity—
Current Ratio3.69
Quick Ratio3.56
Book Value/Sh0.9040 USD
Cash/Share1.159 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.066667:1
Split DateSep 15, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.11M
Insiders21.11%
Institutions12.03%
Technical
SMA 502.587 (-47.8%)
SMA 2002.902 (-53.5%)
Beta0.88
S&P 52W Chg18.16%
Avg Vol (30d)11.55K
Avg Vol (10d)402
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—